Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and GIP , may offer a promising development for weight treatment. Early clinical tests have demonstrated substantial losses in body mass , conceivably outperforming other body composition therapies . Despite this, further study is necessary to thoroughly determine its lastin